AU2015374231B2 - Methods and agents for treating disease - Google Patents

Methods and agents for treating disease Download PDF

Info

Publication number
AU2015374231B2
AU2015374231B2 AU2015374231A AU2015374231A AU2015374231B2 AU 2015374231 B2 AU2015374231 B2 AU 2015374231B2 AU 2015374231 A AU2015374231 A AU 2015374231A AU 2015374231 A AU2015374231 A AU 2015374231A AU 2015374231 B2 AU2015374231 B2 AU 2015374231B2
Authority
AU
Australia
Prior art keywords
thiazol
butan
trifluoromethoxy
ethoxypyridin
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015374231A
Other languages
English (en)
Other versions
AU2015374231A1 (en
Inventor
Lambertus J. W. M. Oehlen
Bijoy Panicker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elicio Therapeutics Inc
Original Assignee
Angion Biomedica Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angion Biomedica Corp filed Critical Angion Biomedica Corp
Publication of AU2015374231A1 publication Critical patent/AU2015374231A1/en
Application granted granted Critical
Publication of AU2015374231B2 publication Critical patent/AU2015374231B2/en
Priority to AU2020257075A priority Critical patent/AU2020257075B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015374231A 2014-12-31 2015-12-29 Methods and agents for treating disease Ceased AU2015374231B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020257075A AU2020257075B2 (en) 2014-12-31 2020-10-21 Methods and agents for treating disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462099120P 2014-12-31 2014-12-31
US62/099,120 2014-12-31
PCT/US2015/067801 WO2016109492A1 (en) 2014-12-31 2015-12-29 Methods and agents for treating disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020257075A Division AU2020257075B2 (en) 2014-12-31 2020-10-21 Methods and agents for treating disease

Publications (2)

Publication Number Publication Date
AU2015374231A1 AU2015374231A1 (en) 2017-07-06
AU2015374231B2 true AU2015374231B2 (en) 2020-07-23

Family

ID=56284982

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015374231A Ceased AU2015374231B2 (en) 2014-12-31 2015-12-29 Methods and agents for treating disease
AU2020257075A Ceased AU2020257075B2 (en) 2014-12-31 2020-10-21 Methods and agents for treating disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020257075A Ceased AU2020257075B2 (en) 2014-12-31 2020-10-21 Methods and agents for treating disease

Country Status (8)

Country Link
US (3) US10287282B2 (https=)
EP (1) EP3240778A4 (https=)
JP (2) JP2018501279A (https=)
CN (1) CN107531631B (https=)
AU (2) AU2015374231B2 (https=)
CA (1) CA2970819A1 (https=)
IL (2) IL252904B (https=)
WO (1) WO2016109492A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
EP3180335B1 (en) 2014-08-11 2021-05-05 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
CA2970819A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp. Methods and agents for treating disease
CN108754141B (zh) * 2018-08-22 2020-12-08 中国科学院上海有机化学研究所 一种萃取有机相及其应用
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4631862B1 (https=) * 1968-10-05 1971-09-17
EP0796846A1 (de) * 1996-03-20 1997-09-24 Bayer Ag 2-Aryl-substituierte Pyridine
US20020045615A1 (en) * 2000-06-21 2002-04-18 Alexander Alanine Benzothiazole derivatives with activity as adenosine receptor ligands
US20030166668A1 (en) * 2001-11-15 2003-09-04 The Institutes For Pharmaceutical Discovery, Inc. A Corporation Of The State Of Delaware Substituted heteroarylalkanoic acids
US20130196967A1 (en) * 2012-01-31 2013-08-01 Alessandra Bartolozzi Heterocyclic compounds as inhibitors of leukotriene production
WO2013181104A2 (en) * 2012-06-01 2013-12-05 The Board Of Trustees Of The Univesity Of Arkansas Alkylation of azoles
US20140018401A1 (en) * 2010-06-01 2014-01-16 Angion Biomedica Corp Cytochrome p450 inhibitors and uses thereof

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2124211B (en) 1982-06-25 1985-12-24 Zyma Sa Dithio compounds pharmaceutical preparations containing them and their use
GB8713861D0 (en) 1987-06-13 1987-07-15 Beecham Group Plc Compounds
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
DE69129611T2 (de) 1990-08-20 1998-12-17 Eisai Co., Ltd., Tokio/Tokyo Sulfonamid-Derivate
TW210334B (https=) 1990-12-12 1993-08-01 Ciba Geigy Ag
DE4126277A1 (de) 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
JPH0616638A (ja) 1992-03-30 1994-01-25 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物およびその医薬用途
BR9305569A (pt) 1992-07-03 1995-12-26 Kumiai Chemical Industry Co Derivados heterocíclicos condensados e herbicidas
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
FR2716192B1 (fr) 1994-02-17 1996-04-12 Rhone Poulenc Agrochimie Dérivés de 2-imidazoline-5-ones fongicides.
US5891916A (en) 1995-06-21 1999-04-06 Takeda Chemical Industries, Ltd. Aromatic hydroxamix acid compounds, their production and use
US5977101A (en) 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US5576349A (en) 1995-11-30 1996-11-19 The General Hospital Corporation Retionoic acid treatment of cardiac arrhythmia
CN1102593C (zh) 1996-06-27 2003-03-05 詹森药业有限公司 N－[4－(杂芳基甲基)苯基]－杂芳基胺类化合物
JPH1017549A (ja) 1996-07-02 1998-01-20 Banyu Pharmaceut Co Ltd 二環性芳香族アミジン誘導体
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
ATE529109T1 (de) 1997-12-22 2011-11-15 Bayer Healthcare Llc Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
DE69831013T2 (de) 1997-12-22 2006-04-20 Bayer Pharmaceuticals Corp., West Haven Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
AU2006201959B2 (en) 1997-12-22 2008-09-04 Bayer Healthcare Llc Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
US20080300281A1 (en) 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
WO1999059586A1 (en) 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
CN1450989A (zh) 2000-07-07 2003-10-22 塔夫茨大学信托人 7－取代的四环素化合物
CA2415169C (en) 2000-07-11 2010-06-01 University Of Maryland, Baltimore Novel c-4 substituted retinoids
WO2002024650A2 (en) 2000-09-19 2002-03-28 Centre National De La Recherche Scientifique (Cnrs) Pyridinone and pyridinethione derivatives having hiv inhibiting properties
WO2002051821A1 (en) 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
US20030199523A1 (en) 2002-02-28 2003-10-23 Snutch Terrance P. Heterocyclic calcium in channel blockers
EP1496892B1 (en) 2002-04-11 2011-01-26 Merck Sharp & Dohme Corp. 1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators
CN1742007A (zh) 2003-01-22 2006-03-01 伊莱利利公司 甾族激素核受体的吲哚衍生物调控剂
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
MXPA06000401A (es) 2003-07-10 2006-03-17 Osi Pharm Inc Derivados de naftileno como inhibidores de citocromo p450.
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US7262318B2 (en) 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
US20050288340A1 (en) 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7579348B2 (en) 2005-02-25 2009-08-25 Pgxhealth, Llc Derivatives of 8-substituted xanthines
AR056339A1 (es) 2005-05-09 2007-10-03 Astrazeneca Ab Derivados benzoicos
PE20071092A1 (es) 2005-12-08 2007-12-10 Aventis Pharma Inc Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
JP2009525955A (ja) 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2007091140A1 (en) 2006-02-06 2007-08-16 Pfizer Products Inc. Substituted phenylsulfamoyl compounds as ppar agonists
CN101041660B (zh) 2006-03-22 2010-05-12 中国科学院化学研究所 1,2-二氢吡啶衍生物、碳苷中间体及其制备方法与应用
CN101405283B (zh) 2006-03-30 2014-06-18 泰博特克药品有限公司 Hiv抑制性5-酰氨基取代的嘧啶类化合物
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
KR101083177B1 (ko) 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
JP2010514672A (ja) 2006-12-29 2010-05-06 武田薬品工業株式会社 Ｃｒｆアンタゴニスト活性を有する縮合複素環化合物
JP4631862B2 (ja) * 2007-03-06 2011-02-16 船井電機株式会社 受信装置
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
KR20100088142A (ko) 2007-11-20 2010-08-06 머크 샤프 앤드 돔 코포레이션 비-뉴클레오사이드 역전사효소 억제제
WO2009081246A2 (en) 2007-12-19 2009-07-02 Pfizer Inc. Bicyclic diamines as nicotinic receptor agonists
JP5369854B2 (ja) 2008-04-21 2013-12-18 住友化学株式会社 有害節足動物防除組成物および縮合複素環化合物
WO2010036404A2 (en) 2008-05-09 2010-04-01 University Of Maryland, Baltimore Novel retinamide retinoic acid metabolism blocking agents
GB0811091D0 (en) 2008-06-17 2008-07-23 Cancer Rec Tech Ltd CYP26 Inhibitors
AR072297A1 (es) * 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US20100041891A1 (en) 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
US8987315B2 (en) 2009-12-31 2015-03-24 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN102153547A (zh) 2010-02-11 2011-08-17 山东轩竹医药科技有限公司 含有并环的噁唑烷酮抗菌素
GB201004739D0 (en) 2010-03-22 2010-05-05 Prosidion Ltd Receptor modulators
AU2011232347B2 (en) 2010-03-24 2015-08-06 Musc Foundation For Research Development Compositions and methods for the treatment of degenerative diseases
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
US20210171515A1 (en) 2010-06-01 2021-06-10 Angion Biomedica Corp. Cytochrome p450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
US8791263B2 (en) 2010-09-17 2014-07-29 Osaka University Cortistatin A analog and use thereof
HUE029002T2 (en) 2010-12-17 2017-01-30 Mitsubishi Tanabe Pharma Corp Continuous aricyclic compounds
JP5959537B2 (ja) 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
JP5881624B2 (ja) 2011-02-18 2016-03-09 信一郎 礒部 蛍光色素
US8218718B1 (en) 2011-06-01 2012-07-10 Elekta Ab (Publ) Radiotherapy and imaging methods and apparatus
EP2736330A4 (en) 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
US20140155381A1 (en) 2011-07-29 2014-06-05 Erkan Baloglu Compounds and methods
TW201317229A (zh) 2011-09-14 2013-05-01 Daiichi Sankyo Co Ltd 稠合雜環衍生物
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2861071B1 (en) 2012-04-04 2017-03-15 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
JP5977349B2 (ja) 2012-06-15 2016-08-24 田辺三菱製薬株式会社 芳香族複素環化合物
WO2014015137A2 (en) 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
CA2886117C (en) 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Indoline compounds and their use as aldosterone synthase inhibitors
US9290476B2 (en) 2012-10-16 2016-03-22 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
WO2014093960A1 (en) 2012-12-16 2014-06-19 Angion Biomedica Corp. Compositions and methods for treating disease
EP3180335B1 (en) 2014-08-11 2021-05-05 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
CA2970819A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp. Methods and agents for treating disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4631862B1 (https=) * 1968-10-05 1971-09-17
EP0796846A1 (de) * 1996-03-20 1997-09-24 Bayer Ag 2-Aryl-substituierte Pyridine
US20020045615A1 (en) * 2000-06-21 2002-04-18 Alexander Alanine Benzothiazole derivatives with activity as adenosine receptor ligands
US20030166668A1 (en) * 2001-11-15 2003-09-04 The Institutes For Pharmaceutical Discovery, Inc. A Corporation Of The State Of Delaware Substituted heteroarylalkanoic acids
US20140018401A1 (en) * 2010-06-01 2014-01-16 Angion Biomedica Corp Cytochrome p450 inhibitors and uses thereof
US20130196967A1 (en) * 2012-01-31 2013-08-01 Alessandra Bartolozzi Heterocyclic compounds as inhibitors of leukotriene production
WO2013181104A2 (en) * 2012-06-01 2013-12-05 The Board Of Trustees Of The Univesity Of Arkansas Alkylation of azoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY, (2007-08-15), Database accession no. 944686-81-1, URL: STN *

Also Published As

Publication number Publication date
EP3240778A1 (en) 2017-11-08
US10287282B2 (en) 2019-05-14
IL252904A0 (en) 2017-08-31
JP2021035975A (ja) 2021-03-04
IL252904B (en) 2021-04-29
JP2018501279A (ja) 2018-01-18
IL281825A (en) 2021-05-31
AU2020257075B2 (en) 2022-06-16
US20180002324A1 (en) 2018-01-04
CN107531631B (zh) 2021-09-03
JP7140813B2 (ja) 2022-09-21
CN107531631A (zh) 2018-01-02
US20190256507A1 (en) 2019-08-22
EP3240778A4 (en) 2018-07-11
US20210323955A1 (en) 2021-10-21
US11434234B2 (en) 2022-09-06
US10851095B2 (en) 2020-12-01
AU2020257075A1 (en) 2020-11-19
AU2015374231A1 (en) 2017-07-06
CA2970819A1 (en) 2016-07-07
WO2016109492A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
US11504359B2 (en) Antifibrotic compounds and uses thereof
AU2020257075B2 (en) Methods and agents for treating disease
WO2010088000A2 (en) Antifibrotic compounds and uses thereof
EP2292227B1 (en) Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity
AU2015301891B2 (en) Cytochrome P450 inhibitors and uses thereof
US9597321B2 (en) Antifibrotic compounds and uses thereof
US20140309234A1 (en) Small molecule anti-fibrotic compounds and uses thereof
HK40021008A (en) Anti-fibrotic compounds and uses thereof
HK1203502B (zh) 抗纤维化的化合物及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired